News

AbstractBackgroundCardiac amyloidosis (CA) is an under-recognized cause of heart failure. Its prevalence in screening studies, and the extent to which selective…

AbstractThe role of autologous stem cell transplantation (ASCT) is central in AL amyloidosis and continues to be defined in the era of newer therapies. To evaluate…

Executive SummaryAnselamimab (CAEL-101) is an investigational, first-in-class fibril-reactive chimeric monoclonal antibody developed by AstraZeneca (following the…

AbstractThis electronic health record-based study highlights distinct diagnostic patterns preceding a diagnosis of light chain (AL) and wild-type transthyretin (…

AbstractBackground: Amyloidosis is an infiltrative cardiomyopathy caused by amyloid deposition into the myocardium. In recent years, recognition of this treatable…

AbstractHereditary transthyretin amyloidosis (ATTRv), the most common form of hereditary amyloidosis, results from autosomal dominant mutations in the TTR gene.…

With the determination of the President no. 655/2026 (Rome, 21 May 2026; published in the Official Gazette on 28 May 2026), the Italian Medicines Agency extended…

AbstractIntroductionTransthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease predominantly affecting older men and is associated with increasing care…

AbstractBackground Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a rare, life‐threatening form of restrictive cardiomyopathy. Access to cardiology providers and…

AbstractBackgroundThe Mayo transthyretin amyloid cardiomyopathy (ATTR-CM) and AMY scores were developed to identify patients at risk for ATTR-CM. However, both were…